| Putting p53 in context ER Kastenhuber, SW Lowe Cell 170 (6), 1062-1078, 2017 | 1723 | 2017 |
| Inducible in vivo genome editing with CRISPR-Cas9 LE Dow, J Fisher, KP O'rourke, A Muley, ER Kastenhuber, G Livshits, ... Nature biotechnology 33 (4), 390-394, 2015 | 556 | 2015 |
| p53 represses the mevalonate pathway to mediate tumor suppression SH Moon, CH Huang, SL Houlihan, K Regunath, WA Freed-Pastor, ... Cell 176 (3), 564-580. e19, 2019 | 316 | 2019 |
| Optimized base editors enable efficient editing in cells, organoids and mice MP Zafra, EM Schatoff, A Katti, M Foronda, M Breinig, AY Schweitzer, ... Nature biotechnology 36 (9), 888-893, 2018 | 314 | 2018 |
| Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors P Lito, A Saborowski, J Yue, M Solomon, E Joseph, S Gadal, ... Cancer cell 25 (5), 697-710, 2014 | 312 | 2014 |
| Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma K Kannan, A Inagaki, J Silber, D Gorovets, J Zhang, ER Kastenhuber, ... Oncotarget 3 (10), 1194, 2012 | 300 | 2012 |
| Deletions linked to TP53 loss drive cancer through p53-independent mechanisms Y Liu, C Chen, Z Xu, C Scuoppo, CD Rillahan, J Gao, B Spitzer, ... Nature 531 (7595), 471-475, 2016 | 261 | 2016 |
| p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer DF Tschaharganeh, W Xue, DF Calvisi, M Evert, TV Michurina, LE Dow, ... Cell 158 (3), 579-592, 2014 | 245 | 2014 |
| Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1 R Ueda, G Kohanbash, K Sasaki, M Fujita, X Zhu, ER Kastenhuber, ... Proceedings of the National Academy of Sciences 106 (26), 10746-10751, 2009 | 205 | 2009 |
| Immunotherapeutic approaches for glioma H Okada, G Kohanbash, X Zhu, ER Kastenhuber, A Hoji, R Ueda, M Fujita Critical Reviews™ in Immunology 29 (1), 2009 | 199 | 2009 |
| Limited environmental serine and glycine confer brain metastasis sensitivity to PHGDH inhibition B Ngo, E Kim, V Osorio-Vasquez, S Doll, S Bustraan, RJ Liang, A Luengo, ... Cancer discovery 10 (9), 1352-1373, 2020 | 170 | 2020 |
| An atlas of substrate specificities for the human serine/threonine kinome JL Johnson, TM Yaron, EM Huntsman, A Kerelsky, J Song, A Regev, ... Nature 613 (7945), 759-766, 2023 | 167 | 2023 |
| IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma D Gorovets, K Kannan, R Shen, ER Kastenhuber, N Islamdoust, ... Clinical Cancer Research 18 (9), 2490-2501, 2012 | 163 | 2012 |
| DNAJB1–PRKACA fusion kinase interacts with β-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma ER Kastenhuber, G Lalazar, SL Houlihan, DF Tschaharganeh, T Baslan, ... Proceedings of the National Academy of Sciences 114 (50), 13076-13084, 2017 | 147 | 2017 |
| 18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers N Palaskas, SM Larson, N Schultz, E Komisopoulou, J Wong, D Rohle, ... Cancer research 71 (15), 5164-5174, 2011 | 145 | 2011 |
| Systemic inhibition of transforming growth factor-β in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines R Ueda, M Fujita, X Zhu, K Sasaki, ER Kastenhuber, G Kohanbash, ... Clinical Cancer Research 15 (21), 6551-6559, 2009 | 141 | 2009 |
| Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells—significant roles of CXCL10 M Fujita, X Zhu, R Ueda, K Sasaki, G Kohanbash, ER Kastenhuber, ... Cancer research 69 (4), 1587-1595, 2009 | 121 | 2009 |
| Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers LGT Morris, BS Taylor, TG Bivona, Y Gong, S Eng, CW Brennan, ... Proceedings of the National Academy of Sciences 108 (47), 19024-19029, 2011 | 113 | 2011 |
| Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent manners X Zhu, BA Fallert-Junecko, M Fujita, R Ueda, G Kohanbash, ... Cancer Immunology, Immunotherapy 59, 1401-1409, 2010 | 106 | 2010 |
| Role of type 1 IFNs in antiglioma immunosurveillance—using mouse studies to guide examination of novel prognostic markers in humans M Fujita, ME Scheurer, SA Decker, HA McDonald, G Kohanbash, ... Clinical Cancer Research 16 (13), 3409-3419, 2010 | 97 | 2010 |
